Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedes Colorado

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Leukemia Research|November 24, 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patientsDavid Martínez-Cuadrón, Cristina Gil, Josefina Serrano, et al.
Bone Marrow Transplantation|January 26, 2022
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMTGiorgia Battipaglia, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Annals of Hematology|November 4, 2023
Feasibility of allogeneic hematopoietic stem cell transplantation in advanced ageSara Fernandez-Luis, David Gomez Lamas, Juan Manuel Cerezo Martin, et al.
Cancers|April 12, 2022
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry ExperienceJorge Labrador, Miriam Saiz-Rodríguez, Dunia de Miguel, et al.
Haematologica|February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaSabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.
Cancers|December 17, 2024
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, David Quintela, Mireia Morgades, et al.
Leukemia Research|April 3, 2020
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry studyCarlos Rodríguez-Medina, David Martínez-Cuadrón, Isabel Cano, et al.
Blood Advances|October 14, 2022
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemiaCatia Simoes, Maria-Carmen Chillon, David Martínez-Cuadrón, et al.
Cancer|February 24, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemiaSusana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, et al.
Haematologica|May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registryDavid Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Leukemia Research|November 24, 2018
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patientsDavid Martínez-Cuadrón, Cristina Gil, Josefina Serrano, et al.
Bone Marrow Transplantation|January 26, 2022
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMTGiorgia Battipaglia, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Annals of Hematology|November 4, 2023
Feasibility of allogeneic hematopoietic stem cell transplantation in advanced ageSara Fernandez-Luis, David Gomez Lamas, Juan Manuel Cerezo Martin, et al.
Cancers|April 12, 2022
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry ExperienceJorge Labrador, Miriam Saiz-Rodríguez, Dunia de Miguel, et al.
Haematologica|February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaSabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.
Cancers|December 17, 2024
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, David Quintela, Mireia Morgades, et al.
Leukemia Research|April 3, 2020
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry studyCarlos Rodríguez-Medina, David Martínez-Cuadrón, Isabel Cano, et al.
Blood Advances|October 14, 2022
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemiaCatia Simoes, Maria-Carmen Chillon, David Martínez-Cuadrón, et al.
Cancer|February 24, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemiaSusana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, et al.
Haematologica|May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registryDavid Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Pageof 5